Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Topics:
Hematologic Malignancies
•
Medical Oncology
•
Myeloma
•
Hematology
Do you recommend observation or initiation of treatment for a standard risk multiple myeloma patient who has been enjoying a treatment-free interval but now has rising paraproteins without evidence of end organ damage?
Related Questions
What induction regimen do you choose for high risk newly diagnosed multiple myeloma in light of the recent high risk focused studies?
How would you approach choosing a regimen for a patient with multiple myeloma refractory to daratumumab and lenalidomide, with severe neuropathy from bortezomib?
Does the presence of osteoporosis change the extent of workup that should be performed for an older patient with otherwise serologically low-risk MGUS?
How would you approach a patient with solitary plasmacytoma with an FLC ratio >100, but a negative bone marrow biopsy and negative PET-CT?
What is your approach to vaccinations and titers for patients with myeloma, who are immunosuppressed and do not have appropriate antibody responses to vaccines?
How do you utilize immunoglobulin testing to affect treatment decisions in patients with myeloma?
How do you discuss harms of MGUS screening with other medical providers?
Do you have any concerns about using checkpoint inhibitors in a patient with myeloma who has a second malignancy?
What are alternative myeloma therapies for patients who are unable to afford lenalidomide or oral cyclophosphamide due to gaps in prescription drug coverage?
What is your approach to MRD testing in the frontline treatment of multiple myeloma?